VIR250117P2500
- 0.04
- 0.000.00%
Vir Biotechnology Newsroom
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
J.P. Morgan Sticks to Their Hold Rating for Vir Biotechnology (VIR)
Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
TD Cowen Maintains Vir Biotechnology(VIR.US) With Buy Rating
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $26
TD Cowen Keeps Their Buy Rating on Vir Biotechnology (VIR)
Vir Biotechnology: Hold Rating Amidst Promising HDV Study Results and Future HBV Developments
Vir Biotechnology Analyst Ratings
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
J.P. Morgan Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $13
Analysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Vir Biotechnology's Promising Hepatitis Programs and Strategic FDA Alignment Justify Buy Rating
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $19
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $19
Vir Biotechnology Analyst Ratings
Needham Reiterates Buy on Vir Biotechnology, Maintains $19 Price Target